You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Mechanistic first-in-human dosability screen for tumor-targeted bispecific antibodies — go/no-go and dosability-margin ranking computed from binding parameters, before any dose exists.
Multi-analyte ADC PK/PD and exposure-driven dose selection — therapeutic window and OBD from conjugate efficacy vs. free-payload toxicity, the toxicology paradigm (not MABEL).